Roche's Avastin wins EU ovarian cancer nod; Mylan cuts 2014 forecast after Q2 profit drop;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Subscribe here, if you please | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in franchise. More | Follow @TracyStaton

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: EMA accepts Pfizer app to expand Prevenar in adults. FierceVaccines story | Follow @CarlyHFierce

> The EU has approved Roche's ($RHHBY) Avastin for the hardest-to-treat form ovarian cancer. More

> Amid a 30% second-quarter profit dive, Mylan ($MYL) trimmed its full-year forecast and revenue outlook. Report (sub. req.)

> Walgreen ($WAG) agreed to acquire the remainder of Alliance Boots for about $5.27 billion and will not move its tax base to the U.K. More

> Astellas Pharma's European division has appointed Simon Dew as chief strategy officer and Jun Kono as VP of corporate strategy and communications. More

> Mallinckrodt ($MNK) raised its full-year guidance on narrower losses in Q3. Report

> Daiichi Sankyo and Charleston Laboratories have announced a collaboration to commercialize the latter's hydrocodone products in the U.S. Report

> The FDA has green-lighted Zydus Cadila's Potassium Citrate ER tablets for use in prevention of kidney stones. Report

> The FDA has approved The Medicines Co.'s ($MDCO) acute skin infection drug. Report

Medical Device News

@FierceMedDev: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @FierceMedDev

@StacyALawrence: Ten big med tech companies add 25,000 jobs in 2013. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. ICYMI from FierceDrugDelivery | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Saving Lives at Birth initiative developing innovative devices to improve infant health in underserved communities. More from National Geographic | Follow @EmilyWFierce

> St. Jude Medical seals the deal on NeuroTherm to gain ground in neuromodulation. News

> NeuroPace RNS Stimulator secures add-on payments from CMS. Story

> Alere to complete strategic review by year-end. Article

Biotech News

@FierceBiotech: Daiichi Sankyo bets up to $650M on Charleston's pain potential. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Article | Follow @JohnCFierce

@DamianFierce: RT @FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @DamianFierce

> Novo picks up the pace with its next-gen insulin, eyeing a 2016 U.S. debut. More

> Hype and hope compete as overnight stardom engulfs untried Ebola drugs. Report

> After a 6-year delay, Medicines Co. bags FDA approval for once-troubled antibiotic. News

Vaccines News

> Bavarian Nordic the only bidder for Canada's smallpox vax supply. Item

> NIH: Ebola vaccine trial could begin as early as September. Report

> Affiris clears Phase I with Parkinson's vaccine candidate. Story

> U.K. and Novartis begin price negotiations on Bexsero. More

> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article

Pharma Manufacturing News

> Alvogen adds Asian manufacturing capacity in $187M Dream Pharma buyout. News

> Impax looking to use $400M cash stash for M&A. Report

> Fresenius awaiting FDA reinspection at plants in NY, India. Story

> Ebola outbreak puts spotlight on tobacco-based drug production. More

> Cubist issues third recall in 12 months after another CMO quality failing. Article

And Finally... Biogenesis founder Anthony Bosch, the man at the center of Major League Baseball's recent performance-enhancing drug scandal, has surrendered to the Drug Enforcement Agency (DEA). Article (sub. req.)

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.